We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sareum Announces Success Milestones in Collaboration with Schering
News

Sareum Announces Success Milestones in Collaboration with Schering

Sareum Announces Success Milestones in Collaboration with Schering
News

Sareum Announces Success Milestones in Collaboration with Schering

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sareum Announces Success Milestones in Collaboration with Schering "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sareum Holdings plc has announced the achievement of key success milestones in its collaboration with Schering AG.

In this collaboration, first announced in October 2005, Sareum has succeeded in using X-ray crystallography to determine, on schedule, the three-dimensional structure of one of Schering’s drug discovery research targets.

As a result of this achievement, Sareum has received success milestone payments.

Sareum will continue to provide structure information to support Schering’s drug discovery research on this target in return for further success milestone payments.

Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, "We are extremely pleased to have achieved these success milestones in this important collaboration."

"The successful determination of this difficult and previously un-solved protein structure further demonstrates our leading position in structure-based drug discovery research."

Advertisement